Why Attend
The 7th Annual Microbiome Connect: USA 2022 is dedicated to showcasing the leading drug development and consumer product platforms applying live microbial consortia, engineered microbes, and microbial-derived metabolites for therapeutic and health applications in patients and consumers.
As the first EMA approved microbiome-targeted therapeutics emerge on the horizon, drug developers will have the opportunity to benchmark their rational drug platforms, targeting validated pathways in gastrointestinal, neurological, metabolic disorders, as well as oncology-based indications.
Furthermore, separate tracks will be committed to developing novel, clinical-validated product formulations for nutritional, digestive wellness, oral and skin care applications.
Join us to hear from microbiome biotechs, pharma voices, investment bodies, consumer product brands and more on how to develop robust, scalable, and reproducible formulations for microbe-derived/-targeting products entering late-stage investigations and reaching for the market.
PAST EVENT SCHEDULE
Our 2022 Agenda will be released soon, please check back again later!
In the meantime, if you'd like to see our past 2021 agenda, please fill out the short form, which will give you access to download the schedule and keep up to date with event highlights. You will discover our leading industry speakers, as well as our new 2021 dedicated manufacturing stream.
By attending our conference, you will learn to:
- Evaluate LBP regulatory challenges to establish principles for batch consistency, meet GMP standards and more with Peter Marks, Director for Biologics Evaluation and Research at the FDA
- Establish what factors are essential in choosing the right CDMO partner to progress to the market with gaining insight from Takeda, Finch Therapeutics and Schauer Biologics
- Scale your product from bench to industrial scale with Christophe Carite, Development Director from 4D Pharma
- Join Scaled Microbiomics, BiomX and Servactus to leverage parallel microbiome modulating approaches to optimize patient outcomes
- Translate the lessons learned in pipeline development to take C. difficile focused therapeutics to the market with Seres, Finch Therapeutics, Evelo Biosciences and Vedanta Biosciences
- Expand possible solutions of tracking the modality of microbiome therapeutics with the identification of different biomarkers from Rebiotix, Takeda and more
- Future-proof your pipeline with insight on future trends from Janssen Pharmaceuticals and Merck Life Sciences
- Improve patient stratification and outcomes as Everimmune, Diwakar Davar and MaaT Pharma examine the applications of the gut microbiome in immuno-oncology
Will you be joining...
Download our Agenda
Conference Packages
Sending Your Team? Group Discounts Available!
Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates
Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off
If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920
Ticket prices increase in
OUR LEADING MICROBIOME SPEAKERS
Peter Marks
Peter Marks received his graduate degree in cell and molecular biology and his medical degree at New York University and completed Internal Medicine residency and Hematology/Medical Oncology training at Brigham and Women’s Hospital in Boston. He has worked in academic settings teaching and caring for patients and in industry on drug development. He joined the FDA in 2012 as Deputy Center Director for CBER and became Center Director in January 2016.
Nikole Kimes
Nikole E. Kimes, Ph.D. is Chief Executive Officer and co-founder of Siolta Therapeutics, a clinical-stage biotech company located in the San Francisco Bay Area. Siolta is developing novel microbiome-based therapeutics and diagnostics for the prevention and treatment of chronic inflammatory diseases, starting with atopic diseases. Dr. Kimes leads the executive, clinical and scientific teams, working with a talented team of scientists and clinicians, blending microbiology, immunology, bioinformatics, and clinical operations expertise to leverage microbiome data for the improvement of patient stratification and development of precision microbial therapeutics. An inventor of Siolta's technology, her research in co-founder Dr. Susan Lynch's lab at UCSF provided the foundation from which the translational research program at Siolta Therapeutics has developed.
Felix Faupel
Diwaker Daver
Bio: Dr. Davar is a translational oncologist whose research interests lies in translational cancer immunotherapy and early-phase clinical trials. He has been instrumental in the development of first-in-human studies evaluating novel agents targeting TIGIT, GITR, TIM-3, CTLA-3 and other immune checkpoints. Based on emerging data implicating intestinal dysbiosis in mediating non-response to PD-1 blockade, he developed a protocol evaluating fecal microbiota transplant in combination with PD-1 blockade to treat PD-1 non-responders. This first-in-human study was selected for funding by Merck to support the clinical costs. Results demonstrating that microbiome modulation reversed primary resistance to anti-PD-1 and augmented anti-tumor immunity were recently published in Science.
Colleen Cutliffe
Joseph Maxwell
Dr. Maxwell trained as an immunologist at Oregon State University and the University of Connecticut Health Center. He spent 15 years supporting early target discovery and program leadership at Amgen, AbbVie, and Finch Therapeutics with an emphasis in inflammatory bowel disease. He is currently an Associate Director of Translational Research and Biomarkers at Takeda supporting clinical programs testing microbiome therapies and other novel modalities in IBD and celiac disease.
Ken Blount
Ken Blount, PhD, is a seasoned director of collaborative research programs in biotech, pharma, clinical, and academic research settings, and his scientific expertise includes antibiotics discovery and development, fecal microbiome analysis, translational medical oncology, and RNA-targeting therapeutics. Prior to joining Rebiotix, Dr. Blount coordinated translational urologic oncology research for the Yale Cancer Center. Previously, he was a cofounder and the Director of Biology at BioRelix, a venture-backed Connecticut biotech that developed new antibiotics to target structured bacterial messenger RNAs. At BioRelix, Dr. Blount led a combined force of internal scientists and external resources that delivered development candidates for treating Clostridium difficile infections. Dr. Blount received his undergraduate degree in biochemistry from the University of Arkansas and earned a PhD in biochemistry from the University of Colorado Boulder, after which he completed an NIH post-doctoral fellowship at the University of California San Diego.
Tue Hodal
Sonia Timberlake
Sonia is the Senior Vice President of Research at Finch Therapeutics. Sonia is an expert at designing NGS-based algorithms for applications in microbial genomics, immunogenomics, and evolution. Prior to joining Finch, she built and managed AbVitro's computational algorithms and infrastructure, supporting high throughput single-cell immune phenotyping and repertoire sequencing technology. This technology platform was acquired by Juno Therapeutics, where Sonia led a multidisciplinary team to harness native adaptive immune responses for developing engineered cell therapies in oncology.
Sonia graduated from Caltech with a B.Sc in Molecular Biology and received her Ph.D. in Biological Engineering from MIT.
Matthew Henn
Matthew Henn is the Executive Vice President and Chief Scientific Officer of Seres Therapeutics. He has over 20 years of combined research experience in microbial ecology, genomics and bioinformatics that spans both environmental and human disease applications. He has been involved in the discovery and clinical development of multiple microbiome therapeutics including all of Seres’ product candidates and has authored over 65 peer-reviewed publications. His research has focused on microbial physiology and the functional role of microbes in both environmental and human disease applications, and on the development of genomic and functional tools to study microbial systems. Prior to helping launch Seres in 2012, he was the Director of Viral Genomics and Assistant Director of the Genome Sequencing Center for Infectious Diseases at the Broad Institute of MIT and Harvard. He has served on various NIH working groups on antimicrobial resistance and microbiome research, as a scientific advisor for NIH’s Viral Pathogen Bioinformatics Resource Center, and as an ad-hoc reviewer and editor of various peer-reviewed journals. He currently serves on the scientific advisory board of Growcentia, Inc., an agricultural microbiome company. Dr. Henn earned his B.S. in ecology and evolutionary sciences from the University of New Hampshire and his Ph.D. from the University of California at Berkeley, where he was a NASA Earth Systems Sciences Fellow, and trained as an NSF Postdoctoral Fellow at Duke University.
Grégory Lambert
Pharmacist and Ph.D. in pharmaceutical technology, Gregory’s carrier is split between Biotech and Pharma where he occupied the positions of Chief Scientific Officer and Chief Executive Officer. Gregory drove the development of a number of drugs, medical devices and food supplement from the laboratory to market. Since 2014, Gregory is the CEO of TargEDys.
Staffan Stromberg
Aaron Anselmo
Anita Patel Jusnes
Carole Schwintner
Denise Kelly
John Weinberg
Rochellys Diaz Heijtz
Romaine Daillere
Romain Daillère completed his PhD in 2015 in the laboratory of Professor Laurence Zitvogel at the Gustave Roussy Cancer Campus (GRCC), Villejuif-Grand Paris/France. His research focuses on the complex interplay between gut microbiota and the efficacy of anticancer regimens. He previously graduated as a biotechnology engineer at the Ecole Supérieure de Biotechnology de Strasbourg (Trinational School of Strasbourg), and worked at the Ragon Institute of MIT, MGH and Harvard in Boston. Co-founder of EverImmune. Co-Inventor of EverImmune Technology. He currently acts as head of the preclinical research of EverImmune.
Rangaprasad Sarangarajan
Ruth Luna Ann
Henrik Bjørn Nielsen
Julius Geopp
Julius Goepp is the founder and CEO of Scaled Microbiomics, LLC, a pre-clinical stage biotech company focused on passive immunotherapy in the microbiome. Dr. Goepp trained in Pediatrics and Emergency Medicine at Children’s Hospital, Boston, and in Pediatric Infectious Disease at Johns Hopkins, where he was active in the promotion of Oral Rehydration Therapy for childhood diarrheal disease. In 2017, he founded Scaled Microbiomics after recognizing the potential for microbiome modulation through the use of little-known avian antibodies, or IgY. Since that time, his energies have been devoted to exploring the characteristics of those antibodies and developing a drug discovery platform based on their use as selective immunomodulators of complex microbiome signaling pathways and event cascades.
Bernat Olle
Dr. Olle is a co-founder and Chief Executive Officer of Vedanta Biosciences. He has been a member of the founding teams of several companies of the PureTech portfolio and served as a member of the Board of Directors of Vedanta Biosciences and Follica Biosciences.
In 2013 Dr. Olle was named "Innovator of the Year" in MIT Technology Review Spain's "Innovators under 35" awards. He completed his doctoral work at the Chemical Engineering Department at MIT, where he developed a novel method for large-scale bacterial culture. During his graduate work, Dr. Olle was awarded the "la Caixa" fellowship. Dr. Olle received his B.S. in Chemical Engineering from Universitat Rovira i Virgili, in the Republic of Catalonia, his M.S. and PhD. in Chemical Engineering Practice from MIT, and his M.B.A. from the MIT Sloan School of Management. He has published his work in journals including Nature and Nature Biotechnology.
James Adams
James B. Adams, Ph.D., is the Director of the Autism/Asperger's Research Program at Arizona State University. His research focuses on the medical causes of autism and how to treat and prevent it including the areas of nutrition (vitamins/minerals, essential fatty acids, carnitine, digestive enzymes, special diets), oxidative stress, gut problems, gut bacteria, toxic metals, and seizures. He has published over 150 peer-reviewed scientific articles, including over 50 related to autism. He is also the President of the Autism Society of Greater Phoenix, the President of the Autism Nutrition Research Center, the co-leader of the Scientific Advisory Committee of the Autism Research Institute, and chair of the Scientific Advisory Board of the Neurological Health Foundation. He has an adult daughter with autism.
Jonathan Solomon
Michal Daniely
Michal is the Director of the Microbiome Initiative within Merck KGaA. In this role, she is responsible for developing technologies and products to advance microbiome research. Over the past 4 years, Michal has been deeply involved in shaping the company’s strategy within the microbiome research field to support the growing need in this market. The company is using core technologies such as microbial fermentation, Next Generation Sequencing (NGS), Mass Spectrometry (MS) for metabolomics & proteomics and more, to develop tools for microbiome researchers around the globe. Michal earned her PhD degree in Human Genetics from the Sackler Medical School, Tel Aviv University, Israel. She is the author of many peer review papers and is bringing significant scientific experience. Prior to joining Merck KGaA, she held different roles in medical device and pharma companies, where she managed the R&D activities.
Wayne Finlayson
Wayne has extensive scientific and commercial corporate experience from over 35years in the pharmaceutical and biotechnology sector. Knowledge in regulatory structures and requirements, and experience in commercialisation of biotechnology, and the practical application of science for the creation of commercial enterprises. Wayne spent his early career years as a post-doctoral research fellow at the University of California, Berkley, following completion of a PhD in Organic Chemistry from La Trobe University. He progressed from initial roles focusing on pure scientific research to more managerial positions in the science and technology sector, including executive director of Both (NASDAQ)and ASX listed companies. Wayne founded Progen Pharmaceuticals in the early 1990’s and was managing director and CEO. After his time at Progen Pharmaceuticals, he worked as a technology investment consultant for high profile clients (including large investment firms) with responsibility for ensuring readiness of investee companies for public listing or other investment. Wayne’s experience, spanning the entire breadth of the biotechnology business spectrum, from post-doctoral researcher, to company founder and CEO, to investment consultant in the Biotechnology sector, means he has a thorough and well-rounded understanding of the challenges and expectations which need to be met to create and successfully commercialise biotechnological and pharmaceutical enterprises.
Stewart Campbell
Dr. Campbell joined Axial in 2016 as Vice President of Research & Development, and was appointed the company’s CEO in February 2021. in 27+ years in the pharma/biotech industry, Dr. Campbell held various leadership roles at Boehringer-Ingelheim, Insmed, Surface Logix, Ancora/Corden Pharma and Axial, Dr. Campbell has played an integral role in the discovery and development of eight clinical stage drug candidates, including the Rho kinase inhibitor belumosudil and TAK-607 (rIGF-1/BP-3). During his career Dr. Campbell has been co-inventor on 20 issued patents. He holds a BSc with Honors in Chemistry from St. Francis Xavier University, a Ph.D. in Organic Chemistry from the Queen’s University (Canada), and did post-doctoral research at Duke University.
Christopher Carite
Christophe is a French citizen graduated in industrial pharmacy (PharmD), Microbiology and Business Administration. He has started his industrial career as plant manager for Lallemand Bacteria Division early ninety, then occupied various positions in R&D and Marketing in B2B of Pharmaceuticals Ingredients. He has joined 4D pharma at the early beginning of the company in 2014 and he has assumed the challenge to produce freeze dried strict anaerobic bacteria at the industrial scale level ( 3500 L fermentor, 5 to 20m2 Freeze dryer) to deliver high concentrated LBPs to patients (> 1010 CFU/caps, shelf life up to 2 years) recognised by several patent families granted. In addition, Christophe has integrated “in house” all 4D pharma Manufacturing and Controls under inspected cGMP.
Right now, he assume the position of Process development/CMC Director and member of 4D Pharma Executive team reporting directly to the CEO.
Federico Bolognani
Dr. Bolognani joined Axial Therapeutics in Nov. 2020 bringing with him over 20 years of experience in translational neuroscience research in academia, pharmaceutical and the biotechnology industries. Most recently, Federico served as the Vice President and Head of Clinical Science at VectivBio in Basel, Switzerland. Prior to VectivBio AG, Dr. Bolognani was VP and Head of Clinical Science at Therachon AG, which was acquired by Pfizer in 2019. Prior to Therachon, Dr. Bolognani held various senior-level positions at Roche. As Translation Medicine Leader, Dr. Bolognani led several of Roche’s programs in neuroscience, including the successful Phase 2 balovaptan program in autism spectrum disorder, which was granted Breakthrough Designation in 2018. Dr. Bolognani received his Ph.D. and M.D. from Universidad Nacional de La Pata, Argentina and has an extensive scientific publication record in translational neuroscience research.
Magali Cordaillat
Dr. Magali Cordaillat-Simmons earned her PhD in 2005 at the Université Paris V René Descartes, France, in Pharmacology, and her second Master’s degree in Pharmaceutical Regulatory Affairs at the Strasbourg Pharmacy School in 2014. Following her doctoral work with Pr. Ariel Gomez in pediatric nephrology at the University of Virginia from 2006 to 2009, Magali joined the newly-created Pharmabiotic Research Institute (PRI), which is an industrial-scientific Association dedicated to supporting the field in the development and registration of microbiome-based medicinal products for the European market. As Scientific and Regulatory Affairs Director, and in close collaboration with the PRI’s more than 80 industry members and academic partners, she oversees the organization’s EU-wide initiatives, which include EU-funded R&I projects, national and EU-level scientific advice request dossiers, and collaborative Task Group work on shared challenges for the field (CMC, standardization efforts, clinical design).
Dr. Rosa Krajmalnik-Brown
Dr. Rosa Krajmalnik-Brown is the director of the Biodesign Center for Health Through Microbiomes and a Professor at the School of Sustainable Engineering and The Built Environment, at Arizona State University. She has a Ph.D. in Environmental Engineering from Georgia Tech. She was awarded an NSF CAREER award, was selected Fulton Engineering Exemplar Faculty, and was recently awarded Arizona Researcher of the year by AZBio highly cited researcher in her field by Web of Science. She has funding for her research from many federal agencies including NIH, DoE, DoD, and NSF. She is a pioneer in research on gut microbiome and autism. She is author of 4 patents and more than 115 peer-reviewed publications. She specializes on molecular microbial ecology for bioremediation, the use of microbial systems for bioenergy production, and the human intestinal microbial ecology and its relationship to obesity, bariatric surgery, metabolism, and autism.
Christopher Missling
Christopher U Missling, PhD is President and CEO of Anavex Life Sciences, has over 20 years of healthcare industry experience within large pharmaceutical and biotech industry. Prior to joining Anavex, he served as Officer at Curis and ImmunoGen and previously at Aventis (now Sanofi). Christopher’s work is dedicated to finding potential cures for rare neurodevelopmental diseases, like Rett syndrome, autism spectrum disorder as well as degenerative diseases like Alzheimer’s and Parkinson’s disease by utilizing precision medicine. Dr. Missling is working with his team to advance new potential treatments through clinical trials involving the respective patient’s advocacy groups. Dr. Missling has an MS and PhD from the University of Munich in Chemistry and an MBA from Northwestern University Kellogg School of Management and WHU.
Dirk Gevers
Dirk Gevers, Ph.D., is Global Head of the Microbiome Solutions team. As a team, we combine our pioneering expertise in the microbiome with the drug discovery, product development, and commercialization know-how of a leading global healthcare company. Together with our colleagues across Janssen and Johnson & Johnson, we have the knowledge and resources to identify the most promising innovations taking place across the microbiome ecosystem and help our partners translate early-stage innovations into product concepts and, ultimately, new solutions with the power to impact human health. Dirk joined from his previous role as Senior Group Leader of Microbial Systems and Communities at the Broad Institute of MIT and Harvard. In this position, Dirk served as a scientific liaison between different organizational components, including the Broad Institute’s data generation platforms and both clinical and analytical collaborators on a number of microbiome-related projects. Dirk’s research efforts at the Broad Institute included the characterization of the microbial imbalance associated with diseases such as Crohn’s disease, type 1 diabetes and colorectal cancer. He was also involved with the National Institutes of Health (NIH) Human Microbiome Project (HMP), holding a leading role in the Data Analysis Working Group, consisting of over 50 investigators focused on human microbiome research. Dirk received his Ph.D. in biochemistry from Ghent University (UGent), Belgium, and completed postdoctoral training at UGent and Massachusetts Institute of Technology (MIT) in bioinformatics, comparative and evolutionary genome analysis and microbial ecolog
Erick Pierstaff
Erick Pierstaff joined the NSF as Program Director in November 2019. Prior to NSF, he was Chief of Operations and led Research and Development at O-Ray Pharma, where he focused on integrating biology and biomedical engineering for the goal of drug development and sustained drug delivery for the treatment of hearing loss and other ear disorders. During his time working at early stage companies, he helped secure both Angel investment and non-dilutive funding in the form of licensing and co-development deals. Additionally, he served as Principal Investigator on several Phase I, II and IIB SBIR grants from the National Institutes of Health and NSF. His research interests have focused on the intersection of the biotic and abiotic, spanning molecular and cell biology, materials science, gene therapy, nanomaterials and drug delivery. Erik has a Ph.D. in Molecular and Cell Biology from the University of California, Berkeley, and a B.S. in Biology from Emory University.
Gokul Swaminathan
Gokul Swaminathan received his Ph.D. degree in microbiology & immunology from Drexel University. At Drexel, he uncovered the interplay between innate immune receptors, non-coding RNAs, HIV-1 infection. For his post-doctoral work, Dr. Swaminathan joined Merck Research Laboratories and trained at the vaccines division at Merck & Co. Inc, West Point, PA. After 2 years of post-doc work, he accepted a senior scientist position within the same group at Merck, West Point. While at Merck WP, Gokul was focused on uncovering the mode-of-action of novel lipid nanoparticle (LNP) based vaccine formulations in the context of viral infections and immuno-oncology. In 2016, Gokul transitioned into a new role at the new Merck Exploratory Science Center (ESC) in Cambridge, MA, where he is currently a principal scientist in the investigational biology group. At the Cambridge ESC, he leads innovative clinical & pre-clinical programs aimed at understanding the influence of the microbiome on the host immune system.
Matthew Henn
Matthew Henn is the Executive Vice President and Chief Scientific Officer of Seres Therapeutics. He has over 20 years of combined research experience in microbial ecology, genomics and bioinformatics that spans both environmental and human disease applications. He has been involved in the discovery and clinical development of multiple microbiome therapeutics including all of Seres’ product candidates and has authored over 65 peer-reviewed publications. His research has focused on microbial physiology and the functional role of microbes in both environmental and human disease applications, and on the development of genomic and functional tools to study microbial systems. Prior to helping launch Seres in 2012, he was the Director of Viral Genomics and Assistant Director of the Genome Sequencing Center for Infectious Diseases at the Broad Institute of MIT and Harvard. He has served on various NIH working groups on antimicrobial resistance and microbiome research, as a scientific advisor for NIH’s Viral Pathogen Bioinformatics Resource Center, and as an ad-hoc reviewer and editor of various peer-reviewed journals. He currently serves on the scientific advisory board of Growcentia, Inc., an agricultural microbiome company. Dr. Henn earned his B.S. in ecology and evolutionary sciences from the University of New Hampshire and his Ph.D. from the University of California at Berkeley, where he was a NASA Earth Systems Sciences Fellow, and trained as an NSF Postdoctoral Fellow at Duke University.
Warren Flood
Ann Marie Conway
Scott Jackson
Daniel van der Lelie
Mark Plinio
Tonya Ward
Traci Kyes
Adam Didier
Yasha Talaga
Manoj Dadlani
Nadine Daou
Laurent Bouillaut
Brian Meehan
Bharat Dixit
Neil Schauer Ph.D
Daniel Menichella
Julie Schwedock
Ryan Wilson
Jason Norman
2021 ATTENDEES
Testimonials
OUR 2021 SPONSORS
Gold Sponsor
Biose Industrie
Website: https://www.biose.com/en/cdmo/
Biose Industrie is a Contract Development and Manufacturing Organization (CDMO), specialised in Live Biotherapeutic Products. Founded in 1951, Biose Industrie has more than 65 years of experience in the development and production of live bacteria based drugs. Company offers lab development specialised in microbiology (anaerobic, aerobic, GMO strains) and is Drug GMP certified for the manufacturing of API (From 300L to 3 500L), clinical batches and commercial drug products (capsules in blisters or pills, sachets).
Quay Pharma
Quay are world known experts in formulation development and clinical manufacturing of live biotherapeutic dosage forms.
No other CDMO has the breadth of knowledge in the formulation services we offer, our clinical trials manufacturing and supply know how as well as our specialist knowledge in providing cost efficient engineering solutions to meet the many challenges that we know can accompany the finished product manufacture of microbial therapies.
Twenty years of focused know how on formulation and analytical development to meet the demands of global regulatory authorities at all clinical phases, has established Quay Pharma as a leading innovator in the fast growing microbial therapies space. We work with bacteria including fastidious anaerobes, multi-species consortia, viruses including bacteriophages and viral vectors and microbially derived drug products such as recombinant peptides and spores. This diversity requires a broad range of expertise, analytical techniques, operational flexibility and handling requirements to ensure safe and efficacious manufacture specifically during manufacturing scaleup for clinical supply.
We are fully licensed for handling BS class 1 and 2 strains as well genetically modified microorganisms. Quay is able to support your GMP manufacture in Europe and is extending this capability to its new facility in the US.
Unlike other CDMO’s Quay offers a specific formulation route that meets your target profile requirements. We know, from experience, that off the shelf solutions, such as intrinsically enteric capsules do not always work and certainly can not provide the protection to your therapeutics potency that other formulation options do.
Get in touch, we look forward to discussing a bespoke solution to meet your therapeutic needs.
Silver Sponsors
Arranta Bio
Website: https://arrantabio.com/
Arranta Bio is a visionary contract development and manufacturing organization (CDMO) that strategically partners with leading microbiome innovators to provide manufacturing, scientific, and regulatory expertise. Our dedicated team, state-of-the-art facilities, and unparalleled resources are crucial for advancing live biotherapeutic products (LBP) from development to commercial launch. We have experience with aerobic, anaerobic, spore-forming, and genetically modified organisms for both single-strain and consortium products. Built specifically for LBP Drug Substance and Drug Product manufacturing, our facilities continue to expand capacity across multiple sites in order to meet the evolving demands of our clients and partners.
CosmosID
Website: www.cosmosid.com
CosmosID® provides end-to-end solutions unlocking the microbiome. A provider of CLIA-certified & ICH-GCP compliant NGS Services and Bioinformatics Solutions, CosmosID offers a range of validated and optimized workflows for research and development.
CosmosID also offers independently validated, industry-leading pipelines for processing metagenomic data, yielding multi-kingdom, strain-level resolution with leading sensitivity and precision. Results can be accessed via CosmosID-HUB, a user-friendly and interactive software for comparative analysis of microbiome data, complete with dynamic charts, visualizations, and statistics.
Millipore Sigma
Website: https://www.sigmaaldrich.com/US/en/products/molecular-biology-and-functional-genomics/microbiome
We are Merck KGaA, Darmstadt, Germany the vibrant science and technology company. Science is at the heart of everything we do, it drives the discoveries we make and the technologies we create.
Our products and services help you safely and efficiently develop and manufacture any therapies. We support everything from biologics to cell and gene therapies.
The latest offering is our microbiome platform. We offer microbiome products as well as one stop solution for microbiome multi-omics services: Metagenomics and Metabolomics services.
Our offering of microbiome workflow products and microbiome multi-omic services support researchers and therapy innovators in their pursuit to understand the microbiome. Our metagenomics services include Amplicon Sequencing (16S,18S, ITS) and Shotgun (WGS). Our metabolomics services include detection of Short chain fatty acids (SCFA), Bile acids and Amino acids (AA). Our unique M-CAMPTM cloud-based bioinformatic interactive platform provides users with an easy-to-use web interface to perform bioinformatic analysis on microbiome samples and download publication-ready graphics and reports.
Event Partner
Phage Consultants
Website: https://phageconsultants.com/
Please visit our website for more information.
Become a Partner
Kisaco Research provides the platform where industry executives can network, learn and meet potential industry partners.
Far from the typical ‘meet-and-greet’ experience, you – as a sponsor or exhibitor – will be positioned as a partner of the event with a focus on the benefits of your product and brand.
Your partnership with Kisaco Research will offer you a strategic approach that is an extension and enhancement of your own marketing and branding efforts. We value your ROI and will work with you directly on your specific goals and targets.
Find out more by calling us at +44 (0)20 3696 2920 or email [email protected]
About Kisaco Research
Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.
Meet industry peers that will help build a career-changing network for life.
Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.
Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.
Invest both in your company growth and your own personal development by signing up to one of our events and get started.